Swallowing and choking difficulties as potential markers of FXTAS progression in FMR1 premutation carriers

N Narueporn Likhitweerawong F Federica Alice Maria Montanaro E Ellery R. Santos J Jun Yi Wang W Waralee Dejputtawat U Udayakumar Narasimhan J Jessica Klusek N Nell Maltman A Andrea Schneider F Flora Tassone R Randi J. Hagerman

Abstract

Abstract Fragile X-associated tremor/ataxia syndrome (FXTAS) affects motor and coordination pathways and is linked to swallowing and choking difficulties, which can lead to aspiration pneumonia, a leading cause of death in late-stage FXTAS. Despite their severity, these issues are under-investigated. This study examined their association with FXTAS stages and potential as markers of disease progression in FMR1 premutation (PM) carriers. A secondary analysis of Genotype-Phenotype cohort data (2017–2025, MIND Institute, UC Davis) examined swallowing/choking problems, FXTAS stage, neuroimaging, and psychological distress (Symptom Checklist-90-Revised; SCL-90-R). Associations between independent and dependent variables were tested using Generalized Estimating Equation (GEE) regression due to their correlated data. The study included 169 PM carriers (mean age 65 ± 10.9 years; 54% male), with approximately 35% reporting swallowing/choking difficulties. After adjusting for age and sex, individuals in the severe stage of FXTAS (stage 4–5) had a significantly higher risk of swallowing/choking problems compared to those without FXTAS (adjusted odds ratio [aOR] = 4.17; 95%CI = 1.28–13.58). PM carriers with swallowing/choking problems showed a significantly increased association with magnetic resonance imaging (MRI) findings of moderate to severe abnormalities in several brain regions, including cerebral atrophy (aOR = 2.69, p  = 0.027), cerebellar atrophy (aOR = 3.34, p  = 0.013), cerebellar white matter hyperintensity (aOR = 3.33, p  = 0.012), and pons white matter hyperintensity (aOR = 3.93, p  = 0.035). Swallowing/choking problems are common in FXTAS, particularly in later stages, and may represent an important clinical marker of disease progression. These patients should be referred to speech-language pathologists for evaluation and treatment. Such interventions could reduce morbidity-mortality associated with these problems.

Article Details

Volume / Issue Vol. 15, Issue 1
Published November 26, 2025
ISSN 2045-2322
Publisher Nature Portfolio

Journal Info

Scientific Reports

Nature Portfolio

ISSN: 2045-2322 Open Access Life Sciences

Authors (11)

N

Narueporn Likhitweerawong

F

Federica Alice Maria Montanaro

E

Ellery R. Santos

J

Jun Yi Wang

W

Waralee Dejputtawat

U

Udayakumar Narasimhan

J

Jessica Klusek

N

Nell Maltman

A

Andrea Schneider

F

Flora Tassone

R

Randi J. Hagerman